HC Wainwright Reiterates Neutral Rating for Eyenovia (NASDAQ:EYEN)

Eyenovia (NASDAQ:EYEN)‘s stock had its “neutral” rating restated by research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $2.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 11.11% from the stock’s previous close. HC Wainwright also issued estimates for Eyenovia’s FY2029 earnings at $1.40 EPS.

Other research analysts also recently issued research reports about the company. Brookline Capital Management reiterated a “hold” rating on shares of Eyenovia in a research report on Friday, November 15th. LADENBURG THALM/SH SH restated a “neutral” rating on shares of Eyenovia in a research note on Monday, November 18th. Finally, William Blair reiterated a “market perform” rating on shares of Eyenovia in a research note on Friday, November 15th.

Eyenovia Stock Down 11.8 %

Shares of NASDAQ:EYEN opened at $1.80 on Thursday. The firm has a market cap of $2.51 million, a PE ratio of -2.47 and a beta of 1.24. The company has a fifty day simple moving average of $6.67 and a 200 day simple moving average of $33.30. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. Eyenovia has a 12-month low of $1.80 and a 12-month high of $205.60.

Eyenovia (NASDAQ:EYEN) last released its earnings results on Tuesday, November 12th. The company reported ($8.80) earnings per share for the quarter, topping the consensus estimate of ($10.40) by $1.60. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same period in the prior year, the company posted ($14.40) earnings per share. On average, equities research analysts anticipate that Eyenovia will post -0.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its stake in Eyenovia by 36.6% in the third quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock valued at $288,000 after buying an additional 149,471 shares during the last quarter. Financial Management Network Inc. acquired a new stake in shares of Eyenovia in the 3rd quarter worth about $39,000. Finally, Nations Financial Group Inc. IA ADV lifted its position in Eyenovia by 78.6% in the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock valued at $47,000 after purchasing an additional 40,000 shares during the last quarter. Institutional investors and hedge funds own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.